Article
Oncology
Luca Visani, Lorenzo Livi, Ivica Ratosa, Miha Orazem, Domen Ribnikar, Calogero Saieva, Carlotta Becherini, Viola Salvestrini, Erika Scoccimarro, Marianna Valzano, Cecilia Cerbai, Isacco Desideri, Marco Bernini, Lorenzo Orzalesi, Jacopo Nori, Simonetta Bianchi, Andrea Morandi, Icro Meattini
Summary: Through a retrospective analysis of data from 132 consecutive HR+/HER2- breast cancer patients, the study found no significant association between concurrent radiotherapy (RT) and adverse events (AEs) in patients treated with CDK4/6 inhibitors (CDK4/6i). Additionally, RT did not affect the dosage reduction or treatment discontinuation rates of CDK4/6i. The results highlight the safety of this combination therapy.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Medicine, General & Internal
Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice Andre, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O'Shaughnessy
Summary: First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Marzia Del Re, Stefania Crucitta, Claudia Omarini, Irene Bargagna, Marta Mongillo, Michela Palleschi, Stefania Stucci, Icro Meattini, Raffaella D'Onofrio, Giulia Lorenzini, Pamela Biondani, Ugo De Giorgi, Camillo Porta, Lorenzo Livi, Salvatore Natalizio, Andrea Fontana, Elena Giontella, Lucia Angelini, Stefano Fogli, Romano Danesi
Summary: This study found that the concomitant use of proton-pump inhibitors does not compromise the efficacy of ribociclib in a real-life setting.
Article
Biochemistry & Molecular Biology
Madhu Sharma, Naresh Mittapelly, Venkatesh Teja Banala, Sandeep Urandur, Shalini Gautam, Disha Marwaha, Nikhil Rai, Neha Singh, Ashutosh Gupta, Kalyan Mitra, Prabhat Ranjan Mishra
Summary: HR+/HER2- metastatic breast cancer is a common and dangerous condition in women. A novel MN system using HA-PVA-PVP microneedle array is developed to deliver RB for breast cancer treatment, reducing toxicity and improving efficacy.
Article
Oncology
Sara M. Tolaney, Young-Hyuck Im, Emiliano Calvo, Yen-Shen Lu, Erika Hamilton, Andres Forero-Torres, Thomas Bachelot, Michela Maur, Angelica Fasolo, Ralph Tiedt, Lisa Nardi, Uz Stammberger, Ahmed M. Abdelhady, Shiling Ruan, Soo Chin Lee
Summary: The study evaluated the safety and tolerability of dual inhibition of the CDK4/6 and PI3K pathways in patients with HR+, HER2(-) ABC, showing that the combination of ribociclib and fulvestrant is safe for treatment. However, triple combinations with alpelisib or buparlisib plus fulvestrant are not recommended for further investigation.
CLINICAL CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Jing Ji, Wenwen Liu, Yuxin Xu, Zhou Xu, Mingxiao Lv, Jing Feng, Jinyu Lv, Xingbei He, Zhen Zhang, Mengru Xie, Aixin Jing, Xiujun Wang, Jinming Ma, Bin Liu
Summary: A novel derivative of Ribociclib, WXJ-202, was designed and synthesized to target CDK4/6 in breast cancer cells. WXJ-202 exhibited inhibitory effects on cell proliferation, colony formation, migration, and invasion, as well as induced apoptosis and cell cycle arrest. The expression levels of proteins related to the CDK4/6-Rb-E2F pathway were decreased by WXJ-202. Moreover, WXJ-202 showed significant anti-tumor activity in transplantation tumor models.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
C. Louwrens Braal, Elisabeth M. Jongbloed, Saskia M. Wilting, Ron H. J. Mathijssen, Stijn L. W. Koolen, Agnes Jager
Summary: CDK 4/6 inhibitors are a new class of drugs that interrupt proliferation of malignant cells by inhibiting progression through the cell cycle. This article reviews the clinical pharmacokinetic and pharmacodynamic profiles of these inhibitors and discusses important future directions for their clinical applicability.
Article
Oncology
Luca Nicosia, Vanessa Figlia, Nicola Ricottone, Francesco Cuccia, Rosario Mazzola, Niccolo Giaj-Levra, Francesco Ricchetti, Michele Rigo, Fatemeh Jafari, Stefano Maria Magrini, Andrea Girlando, Filippo Alongi
Summary: This study aims to demonstrate the effectiveness of stereotactic body radiotherapy (SBRT) in delaying the switch to a subsequent systemic treatment in patients with oligoprogressive breast cancer. The results show that SBRT can delay the progression of treatment, but patient selection is necessary, and several predictive factors for individualized treatment have been identified.
CLINICAL & EXPERIMENTAL METASTASIS
(2022)
Article
Biochemistry & Molecular Biology
Michele Iuliani, Sonia Simonetti, Giulia Ribelli, Andrea Napolitano, Umile Giuseppe Longo, Bruno Vincenzi, Paolo Orsaria, Vincenzo Denaro, Giuseppe Tonini, Daniele Santini, Pantano Francesco
Summary: This study compared the potential effects of three CDK4/6 inhibitors on the breast cancer bone microenvironment. The results showed that these inhibitors exerted similar inhibitory effects on the differentiation of bone resorption cells and the expression of bone resorption markers, without affecting cell viability. However, they did not affect the ability of bone formation cells to produce bone matrix, although higher doses of two inhibitors reduced the viability of these cells. In co-culture models of breast cancer and bone cells, palbociclib demonstrated a lower anti-tumor effect compared to the other two inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Isabel Mayayo-Peralta, Beatrice Faggion, Liesbeth Hoekman, Ben Morris, Cor Lieftink, Isabella Goldsbrough, Lakjaya Buluwela, Joseph C. Siefert, Harm Post, Maarten Altelaar, Roderick Beijersbergen, Simak Ali, Wilbert Zwart, Stefan Prekovic
Summary: Treatment resistance and disease progression are common challenges in breast cancer patients, particularly those with mutations in the oestrogen receptor-alpha gene. This study identifies ribociclib as an effective inhibitor for breast cancer cells, inducing senescence and reducing sensitivity to chemotherapy. Additionally, the maintenance of cell viability through the EGFR signaling pathway following ribociclib treatment offers potential therapeutic opportunities.
Article
Oncology
Mahtab Afsharzadeh, Jaleh Varshosaz, Mina Mirian, Farshid Hasanzadeh
Summary: This study successfully prepared SLC7A5 transporters targeted liposomes by conjugating amino acids to the liposomes. The targeted liposomes showed increased cytotoxicity on MCF-7 cells and more significant interruption of the cell cycle.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Navraj S. Nagra, Elena Tsangaris, Jessica Means, Michael J. Hassett, Laura S. Dominici, Jennifer R. Bellon, Justin Broyles, Robert S. Kaplan, Thomas W. Feeley, Andrea L. Pusic
Summary: The study used time-driven activity-based costing to calculate the complete cost of breast cancer care, including initial treatment planning, chemotherapy, radiation therapy, surgical resection and reconstruction, and ancillary services across multiple hospital sites. Surgical care and chemotherapy had higher base costs, with personnel expenses being the major contributor to surgical care costs.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Patrick Neven, Gabe S. Sonke, Guy Jerusalem
Summary: In patients with HR+/HER2- ABC, combining ribociclib with fulvestrant has shown to significantly improve PFS and OS. The safety profile of this combination is manageable, with myelosuppression being a common toxicity. The optimal usage and post-CDK4/6i progression strategies are still being investigated.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Article
Oncology
Stanislas Quesada, Pascal Fenoglietto, Sophie Gourgou, Claire Lemanski, Roxana Draghici, Norbert Ailleres, Jessica Prunaretty, David Azria, Celine Bourgier
Summary: This observational study evaluated the efficacy, safety, and feasibility of volumetric modulated arc therapy (VMAT) for synchronous bilateral breast cancers (SBBC). The results showed that VMAT provided adequate target volume coverage and organ at risk sparing. Acute toxicities were mild, and long-term survival rates were favorable.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Amelie Aboudaram, Pierre Loap, Delphine Loirat, Syrine Ben Dhia, Kim Cao, Alain Fourquet, Youlia Kirova
Summary: The study shows that the combination of locoregional breast radiotherapy with dual HER2 blockade of Pertuzumab and Trastuzumab was well tolerated in metastatic breast cancer patients, suggesting that radiotherapy can be safely administered to HER2-positive breast cancer patients.
Article
Otorhinolaryngology
Stefano Ursino, Elisa Calistri, Francesca De Felice, Pierluigi Bonomo, Isacco Desideri, Pierfrancesco Franco, Francesca Arcadipane, Caterina Colosimo, Rosario Mazzola, Marta Maddalo, Alessandra Gonnelli, Giulia Malfatti, Riccardo Morganti, Daniela Musio, Fabiola Paiar
Summary: This study aimed to investigate changes in M.D. Anderson Dysphagia Inventory (MDADI) scores in patients with naso- and oropharynx cancer after radiochemotherapy using IMRT with sparing of swallowing organs at risk (SWOARs). The results showed a slight decline in MDADI scores after treatment in the optimal group, and a significant and clinically meaningful improvement in the adequate/poor group. Therefore, dose optimization to SWOARs can minimize treatment-related symptoms in patients with optimal deglutition-related quality of life and help those with adequate/poor deglutition-related quality of life recover from cancer dysphagia.
Article
Oncology
Livia Marrazzo, Icro Meattini, Gabriele Simontacchi, Lorenzo Livi, Stefania Pallotta
Summary: Multiple phase 3 trials have shown that partial breast irradiation is not inferior to whole breast irradiation in terms of local control and has similar or reduced toxicity. The 5-fraction regimen has gained interest, especially during the COVID-19 pandemic. The APBI-IMRT-Florence trial schedule of 30 Gy in 5 fractions appears to be a safe and effective option for patients with early breast cancer.
PRACTICAL RADIATION ONCOLOGY
(2023)
Review
Oncology
Icro Meattini, Kyubo Kim, Lorenzo Livi
Summary: The study compares the effectiveness of intensity-modulated accelerated partial breast irradiation with whole breast irradiation. The former shows excellent long-term disease control and favorable safety and cosmetic outcomes. A 5-fraction schedule is the standard regimen, providing a compromise between efficacy, safety, and quality of life.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2023)
Article
Oncology
Giulio Francolini, Giulio Frosini, Vanessa Di Cataldo, Beatrice Detti, Maria Grazia Carnevale, Marco Banini, Anna Peruzzi, Viola Salvestrini, Luca Visani, Emanuela Olmetto, Carlotta Becherini, Andrea Allegra, Luca Burchini, Vieri Scotti, Monica Mangoni, Icro Meattini, Isacco Desideri, Lorenzo Livi
Summary: This study aimed to explore predictive factors of fitness to taxane chemotherapy in older adult patients. Data from patients aged 70 years old and above were collected, and it was found that G8 score is an important predictor for tolerability of taxane chemotherapy.
JOURNAL OF GERIATRIC ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Leonardo Calamandrei, Luca Mariotti, Eleonora Bicci, Linda Calistri, Eleonora Barcali, Martina Orlandi, Nicholas Landini, Francesco Mungai, Luigi Bonasera, Pierluigi Bonomo, Isacco Desideri, Leonardo Bocchi, Cosimo Nardi
Summary: The aim of this study was to investigate MRI biomarkers for the assessment of RT-induced xerostomia. Patients who underwent radiation therapy for oropharyngeal cancer were divided into three groups according to the severity of their xerostomia. Conventional and functional MRI did not yield statistically significant results, but texture analysis on ADC maps allowed the distinction between different degrees of severity of RT-induced xerostomia in the pre-RT population.
APPLIED SCIENCES-BASEL
(2023)
Article
Oncology
Icro Meattini, Rejane de Oliveira Franco, Viola Salvestrini, Tarek Hijal
Summary: Breast cancer is the most common cancer in women worldwide, and significant progress has been made in understanding its biology and pathology. A personalized conservative approach is currently used based on individual patient risk. Partial-breast irradiation has been developed to reduce treatment morbidity while maintaining the ability to decrease local recurrences. However, there are still questions to be answered and a one-treatment-fits-all approach is not appropriate for this heterogeneous disease.
Article
Oncology
Carl Sars, Helena Sackey, Jan Frisell, Paul W. Dickman, Fredrik Karlsson, Isabelle Kindts, Gustavo Nader Marta, Ruffo Freitas-Junior, Tove Filtenborg Tvedskov, Loay Kassem, Ahmed S. Ali, Hanna Ihalainen, Mathias Neron, Michalis Kontos, Orit Kaidar-Person, Icro Meattini, Anne Brecht Francken, Frederieke van Duijnhoven, Ingvild Ona Moberg, Tanja Marinko, Attila Kollar, Mahbubl Ahmed, Dennis Remoundos, Jenny Banks, Reshma Jagsi, Lesly A. Dossett, Ebba K. Lindqvist
Summary: Phyllodes tumors of the breast are rare fibroepithelial lesions classified as benign, borderline or malignant. Current clinical practice in managing these tumors shows considerable variation, indicating a need for education and further research to establish appropriate surgical margins, follow-up time, and a multidisciplinary approach.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Oncology
Alessandra Fozza, Fiorenza De Rose, Maria Carmen De Santis, Icro Meattini, Bruno Meduri, Elisa D'angelo, Damiano Dei, Vanessa Figlia, Eliana La Rocca, Piero Fregatti, Camilla Satragno, Liliana Belgioia, Niccolo Giaj-Levra
Summary: In this review, current available technologies in the management of breast cancer are summarized. These technologies include postoperative partial breast cancer treatment, preoperative stereotactic partial breast irradiation, image-guided radiotherapy, hybrid magnetic resonance linear accelerator, and artificial intelligence. The overall level of evidence about these new technologies is still low in patients with breast cancer, although some advances are potentially very interesting for further development.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Letter
Oncology
Valerio Nardone, Tomer Meirson, Francesca De Felice, Icro Meattini
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Elisa Scola, Guido Del Vecchio, Giorgio Busto, Andrea Bianchi, Ilaria Desideri, Davide Gadda, Sara Mancini, Edoardo Carlesi, Marco Moretti, Isacco Desideri, Giovanni Muscas, Alessandro Della Puppa, Enrico Fainardi
Summary: The non-enhancing peritumoral area (NEPA) is defined as the hyperintense region in T2-weighted and fluid-attenuated inversion recovery (FLAIR) images surrounding a brain tumor. NEPA analyses using conventional and advanced MRI techniques have shown promise in the differential diagnosis of brain tumors and predicting prognosis and treatment response. An update on this topic is needed due to the rapid technological advancements in advanced MRI imaging.
Article
Radiology, Nuclear Medicine & Medical Imaging
Eleonora Bicci, Cosimo Nardi, Leonardo Calamandrei, Eleonora Barcali, Michele Pietragalla, Linda Calistri, Isacco Desideri, Francesco Mungai, Luigi Bonasera, Vittorio Miele
Summary: Texture analysis on MRI images can differentiate inflammation, fibrosis, and residual cancer in patients with naso-oropharynx carcinoma after radiochemotherapy. Two features (Energy and Grey Level Non-Uniformity) on T1 images and five features on ADC maps were found to be statistically significant for distinguishing positive and negative patients. The reduction in feature values correlated with a good response to therapy.
Review
Chemistry, Multidisciplinary
Ilaria Morelli, Carlotta Becherini, Marco Banini, Marianna Valzano, Niccolo Bertini, Mauro Loi, Giulio Francolini, Icro Meattini, Viola Salvestrini, Pierluigi Bonomo, Lorenzo Livi, Isacco Desideri
Summary: This review evaluates the role of radiomic features from conventional imaging in assessing the HPV status of OPSCC patients. The study finds that radiomic models can play a complementary role in determining HPV status, with MRI and CT-based models showing comparable efficacy.
APPLIED SCIENCES-BASEL
(2023)
Article
Oncology
Jonas Willmann, L. Appelt, Panagiotis Balermpas, G. Baumert, Dirk de Ruysscher, Morten Hoyer, Coen Hurkmans, Orit Kaidar-Person, Icro Meattini, Maximilian Niyazi, Philip Poortmans, Nick Reynaert, Stephanie Tandini-Lang, Yvette van der Linden, Carsten Nieder, Nicolaus Andratschke
Summary: This study investigated the patterns of care for re-irradiation internationally and found significant heterogeneity across anatomical regions, highlighting the need for high-quality evidence from prospective studies to guide treatment decisions and establish safe cumulative dose constraints.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Giulio Francolini, Maria Grazia Carnevale, Vanessa Di Cataldo, Mauro Loi, Beatrice Detti, Carolina Orsatti, Luisa Caprara, Niccolo Bertini, Victoria Lorenzetti, Emanuela Olmetto, Carlotta Becherini, Luca Visani, Viola Salvestrini, Gabriele Simontacchi, Daniela Greto, Pierluigi Bonomo, Raffaela Doro, Laura Masi, Isacco Desideri, Icro Meattini, Sergio Serni, Lorenzo Livi
Summary: This study retrospectively collected data from 101 patients with locally recurrent prostate cancer who underwent re-irradiation. The results showed that CyberknifeR rSBRT had promising oncological outcomes and low toxicity in this patient cohort.
